NOVA2

Across TCGA pan-cancer cohorts, NOVA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOVA2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NOVA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOVA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where NOVA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.761	0.973	.005	38	view →
CCRCC	DFS	Tertile	III,IV	0.806	0.417	.004	33	view →
UCEC	OS	Median	III,IV	0.408	1.000	.003	24	view →
GBM	OS	Tertile	All	0.663	0.337	<.001	18	view →
PDAC	DFS	Quartile	All	0.492	0.317	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NOVA2–LUAD (DFS)

Open the LUAD breakdown →